4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

- INFLAM MOTION enrolled 129 patients with knee osteoarthritis associated with synovitis across Europe, the United States and Canada, targeting an inflammatory phenotype associated with structural progression in knee osteoarthritis.

- One of the first randomized clinical studies designed to combine symptomatic improvement with objective imaging biomarker assessment of synovial tissue thickening and inflammation, a biological process linked to disease progression

- Topline results expected by the end of December 2026

4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progression in knee osteoarthritis.